Editorial comment: Glycoprotein IIb/IIIa inhibitors: More different than alike?

Catheterization and Cardiovascular Interventions

Volumn 53, Issue 3, 2001, Pages 304-307

  Stone, Gregg W ^a  

^a CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; TIROFIBAN; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; PEPTIDE; TYROSINE;

ANGIOPLASTY; CLINICAL TRIAL; CORONARY STENT; DRUG INDICATION; EDITORIAL; HEART CATHETERIZATION; HEART MUSCLE ISCHEMIA; HOSPITALIZATION; HUMAN; CORONARY ARTERY DISEASE; DRUG ANTAGONISM; NOTE;

ANTIBODIES, MONOCLONAL; CORONARY DISEASE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; TYROSINE;

EID: 0035403415     PISSN: 15221946     EISSN: None     Source Type: Journal    
DOI: 10.1002/ccd.1171     Document Type: Editorial

References (25)

1. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
2. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine
3. Platelet glycoprotein IIb/IIIa receptor blockade and low dose heparin during percutaneous coronary revascularization
4. Randomized placebo controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE Study
5. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade
6. Randomized placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II, Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis-II
7. High dose eptifibatide (integrilin) in coronary stent implantation: One year results of the ESPRIT trial
8. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty
9. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction
10. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction
11. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes
12. Glycoprotein IIb/IIIa receptor inhibitors: Putting the EPIC, IMPACT II, RESTORE and EPILOG trials into perspective
13. IIb's are not IIb's
14. Specific platelet mediators and unstable coronary artery lesions. Experimental evidence and potential clinical implications
15. Comparison of early invasive versus early conservative strategies in patients with unstable angina and non-ST elevation myocardial infarction treated with early glycoprotein IIb/IIIa inhibition: The TACTICS/TIM I-18 Trial
16. The GUSTO-IV trial
17. Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention
18. Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes
19. Impact of abciximab versus eptifibatide on length of hospital stay for PCI patients
20. TARGET: Do tirofiban and reopro give similar efficacy outcomes trial
21. Comparative study of light transmission aggregometry and automated bedside platelet function assays in patients undergoing percutaneous coronary intervention and receiving abciximab, eptifibatide, or tirofiban
22. Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions
23. Atherosclerotic plaque burden and CK-MB enzyme elevation after coronary interventions: An intravascular ultrasound study of 2,256 patients
24. Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention